The pharmaceutical industry is doubling down on its campaign to force Colombia to alter its policies toward pricing and patents for medicines by enlisting the support of a congressional ally.
Over the past month, industry groups urged U.S. trade officials to place Colombia on a list of countries that purportedly fail to enforce intellectual property rights. Trade officials responded by warning Colombia that changes are needed prior to an upcoming meeting to discuss membership in the Organization for Economic Cooperation and Development, an intergovernmental trade group.
About the Author Reprints
